Related Experiment Video
Updated: Feb 6, 2026
12:03
Fertility Preservation in Patients with Severe Ovarian Dysfunction
Published on: March 25, 2021
5.0K
Endothelial dysfunction in patients with eosinophilic granulomatosis with polyangiitis
Renata Pacholczak1,2, Stanisława Bazan-Socha3, Teresa Iwaniec3
1Department of Anatomy, Jagiellonian University Medical College, Cracow, Poland.
Clinical Rheumatology
|August 23, 2018
Summary
Eosinophilic granulomatosis with polyangiitis (EGPA) patients exhibit endothelial dysfunction, indicated by elevated VCAM-1 and thrombomodulin levels and reduced FMD. This inflammatory endothelial injury is linked to EGPA pathogenesis and cardiovascular risks.
Area of Science:
- Cardiovascular Medicine
- Rheumatology
- Immunology
Background:
- Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis associated with asthma and eosinophilia.
- Endothelial dysfunction is documented in other vasculitides but not well-established in EGPA.
- Cardiovascular disease is a significant concern in EGPA patients.
Purpose of the Study:
- To investigate endothelial dysfunction in EGPA patients in remission.
- To assess markers of endothelial injury and inflammation in EGPA.
- To explore the relationship between endothelial dysfunction and disease characteristics.
Main Methods:
- Cross-sectional study comparing 30 EGPA patients with 58 age/sex-matched controls.
- Measured serum levels of VCAM-1, IL-6, and thrombomodulin.
- Assessed flow-mediated dilatation (FMD) and intima-media thickness (IMT) via ultrasonography.
Main Results:
- EGPA patients showed significantly higher VCAM-1 and thrombomodulin levels.
- EGPA patients exhibited significantly lower FMD, indicating endothelial dysfunction.
- Endothelial injury markers correlated with inflammation and impaired kidney function.
Conclusions:
- EGPA is characterized by inflammatory endothelial injury, potentially contributing to disease pathogenesis.
- Endothelial dysfunction in EGPA patients increases cardiovascular event risk.
- Immunosuppressive therapy and preventive interventions are crucial for managing cardiovascular risks in EGPA.
Related Concept Videos
01:13Patient-centered Care
3.1K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.1K
01:15Drug Dosing: Geriatric Patients
278
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
278
01:21Drug Dosing: Obese Patients
268
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
268
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
239
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
239
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
266
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
266
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
314
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
314